Sign In
Buy IKT
$1.70
-0.0100 (-0.585%)
At Close: Jun 02, 2026
New Strong Buy Stocks for January 26th
07:26am, Friday, 26'th Jan 2024
IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Monday, 22'nd Jan 2024
Inhibikase Therapeutics, Inc. (IKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript
05:38pm, Wednesday, 15'th Nov 2023
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2023 Earnings Conference Call November 15, 2023 8:00 AM ET Company Participants Alex Lobo - IR Milton Werner - CEO Joseph Frattaroli - CFO Conference Cal
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
09:28am, Tuesday, 07'th Nov 2023
This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" r
Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
08:05am, Tuesday, 22'nd Aug 2023
BOSTON and ATLANTA , Aug. 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor
Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
08:05am, Monday, 07'th Aug 2023
BOSTON and ATLANTA , Aug. 7, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t
Inhibikase Therapeutics to Present at the LD Micro Invitational XIII
08:05am, Tuesday, 30'th May 2023
BOSTON and ATLANTA , May 30, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor
Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
08:05am, Monday, 08'th May 2023
BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor th
Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
08:05am, Thursday, 04'th May 2023
BOSTON and ATLANTA , May 4, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t
Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase
08:30am, Friday, 21'st Apr 2023
BOSTON and ATLANTA , April 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor
Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
05:15pm, Thursday, 23'rd Mar 2023
BOSTON and ATLANTA , March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibito
Penny Stocks To Buy? 4 To Watch Now After Big News
09:33am, Thursday, 16'th Mar 2023
Penny stocks to watch after big news this week The post Penny Stocks To Buy? 4 To Watch Now After Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?
09:56am, Thursday, 26'th Jan 2023
Inhibikase Therapeutics (NASDAQ: IKT ) stock is falling on Thursday after the company announced a registered direct offering and private placement. Starting with the registered direct offering up 6,74
Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript
09:55am, Tuesday, 15'th Nov 2022
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2022 Earnings Conference Call November 15, 2022 8:00 AM ET Company Participants Alex Lobo – Stern Investor Relations Milton Werner – President and Ch
Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
08:00am, Tuesday, 08'th Nov 2022
BOSTON and ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t
